Therapeutic Considerations for Docetaxel and Paclitaxel in Metastatic Breast Cancer
Breast cancer is the main source of death among women. Currently, 77% of women diagnosed with breast cancer are age 50 and older; however, it is projected that approximately 66% of the new cases diagnosed will occur in women younger than 65. Several clinical trials have assessed the wellbeing and adequacy of taxanes along with their tolerability in patients with metastatic cancer (MBC) The overview of these Paclitaxel and Docetaxel, the mechanism of action, pharmacokinetics and pharmacodynamics, dose and administration, adverse effects, clinical potency, and sufferable profiles combination therapies, the pathological complete response of these taxanes are included. The different novel formulations of taxanes are formulated from nanoparticles, polyglutamate, liposomes to improve the wellbeing and adequacy taxanes to reduce their toxicities. Single-agent research located with docetaxel and paclitaxel in metastatic breast most cancers show clinically huge antitumor motion even in the advanced stage, heavily pretreated, safe, as properly as in refractory diseases. This action is likewise clear with taxane-based combination regimens. Serious hematologic and nonhematologic toxicities are incompatible, with different toxicities noted dependent on the portion and weekly regimen selected. Weekly docetaxel and paclitaxel regimens speak to important helpful treatment options for women suffering from metastatic breast cancer and have entered assessment as a major aspect of adjuvant treatment for this disease Toxicity associated with taxanes chemotherapy are based totally on the dose schedules and weekly regimen selected and the most frequent toxicities related with these marketers include myalgia, peripheral neuropathy, neutropenia, etc Docetaxel retains in tumor cells for longer duration when compared to paclitaxel because of its slow efflux and large amounts of uptake into the cell which explains its more benefits when compared to paclitaxel. Clinical studies conducted so far suggested a more benefit to risk ratio for docetaxel when compared to paclitaxel. This article reviews mainly different actions exhibited by taxanes in the therapy of metastatic breast cancer and others on stages of cancer along with the toxicities associated with these agents.
: D. Mauri, N. Pavlidis, J. P. A. Ioannidis, Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis. J. Natl. Cancer Inst. 97, 188–194 (2005).
: M. Van de Wiel et al., Neoadjuvant systemic therapy in breast cancer: Challenges and uncertainties. Eur. J. Obstet. Gynecol. Reprod. Biol. 210, 144 –156 (2017).
: J.Gralowetal., Preoperative therapy in invasive breast cancer: Pathological assessment and systemic therapy issues in operable disease. J. Clin. Oncol. 26, 814 –819 (2008).
: G. von Minckwitz et al., Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J. Clin. Oncol. 30, 1796–1804 (2012).
: F. Valet et al., Challenging single- and multi-probesets gene expression signatures of pathological complete response to neoadjuvant chemotherapy in breast cancer: Experience of the REMAGUS 02 phase II trial. Breast 22, 1052–1059 (2013).
: Schiff PB, Fant J, Horowitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 227: 665–667.
: Wani MC, Taylor HL, Wall ME. Plant antitumor agents VI. The isolation and structure of taxol: a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971; 93: 2325–2327.
: Bernstein B. Docetaxel as an alternative to paclitaxel after acute hypersensitivity reactions. Ann Pharmacother 2000; 34: 1332–1335
: Nuijen B, Bouma M, Schellens JH, Beijnen JH. Progress in the development of alternative pharmaceutical formulations of taxanes. Invest New Drugs 2001; 19: 143–153.
: Jackisch C, Eibach H, Knuth A et al. Phase II trial of docetaxel weekly as dose-dense treatment in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2000; 18:417.
: Kim Y, Takatsuka Y, Tanigawara Y et al. Weekly docetaxel for patients with recurrent breast cancer: clinical results and pharmacokinetic/pharmacodynamic assessment. Proc Am Soc Clin Oncol 2000; 18:436a.
: Ford HER, Miles D, Makris A et al. A phase II study of a weekly docetaxel schedule in patients with anthracycline pretreated metastatic breast cancer. Ann Oncol 2002;13(suppl 5):65.
: Ramos M, Gonzalez-Ageitos A, Amenedo M et al. Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment. J Chemother 2003; 15:192–197.
: Mey U, Gorschluter M, Ziske C et al. Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial. Anticancer Drugs 2003; 14:233–238.
: Maisano R, Mare M, Zavattieri M et al. Is weekly docetaxel an active and gentle chemotherapy in the treatment of metastatic breast cancer? Anticancer Res 2003; 23:1923–1926.
: Kuroi K, Bando H, Saji S et al. Protracted administration of weekly docetaxel in metastatic breast cancer. Oncol Rep 2003; 10:1479–1484.
: Burstein HJ, Manola J, Younger J et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000;18: 1212–1219.
: Stemmler J, Mair W, Stauch M et al. Weekly docetaxel with or without corticosteroid premedication as first or second-line treatment in patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2002; 21:58a.
: Aihara T, Kim Y, Takatsuka Y. Phase II study of weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2002; 13:286–292.
: Hainsworth JD, Burris HA 3rd, Yardley DA et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001; 19:3500–3505.
: Estevez LG, Cuevas JM, Anton A et al. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study. Clin Cancer Res 2003; 9:686–692.
: D’Hondt R, Paridaens R, Wildiers H et al. Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer
: Ito Y, Aiba K, Horikoshi N et al. Dose-finding phase I study of simultaneous weekly infusion with doxorubicin and docetaxel in patients with advanced breast cancer. Int J Clin Oncol 2001; 6:242–247.
: Wenzel C, Locker GJ, Pluschnig U et al. Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer. Cancer Chemother Pharmacol 2002; 50:155–159.
: Yardley DA, Whitworth P, Greco FA et al. Neoadjuvant gemcitabine, epirubicin, and docetaxel (GET). Preliminary results from a multi-center phase II trial in inflammatory and locally advanced breast cancer. Breast Cancer Res Treat 2003;82(suppl 1): S54.
: Holmes FA, Blum JL, Kruger S et al. Phase II study of weekly pegylated liposomal doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer. Breast Cancer Res Treat 2003;82(suppl 1): S130.
: Brugnatelli S, Danova M, De Bella MT et al. Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase I study. Oncology 2002; 62:33–38.
: Frasci G, Comella P, D’Aiuto G et al. Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG). Ann Oncol 2000; 11:367–371.
: Fountzilas F, Nicolaides C, Bafaloukos D et al. Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group phase II study. Cancer Invest 2000; 18:503–509.
: Mavroudis D, Malamos N, Alexopoulos A et al. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group. Ann Oncol 1999; 10:211–215.
: Laufman L, Spiridonidis C, Carman L et al. Second-line chemotherapy with weekly gemcitabine (GEM) and monthly docetaxel (DOC) in patients (pts) with metastatic breast cancer (MBC): a phase II study. Pro Am Soc Clin Oncol 2000; 18:1968a.
: Kornek GV, Ulrich-Pur H, Penz M et al. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor. J Clin Oncol 2001; 19:621–627.
: Esteva FJ, Valero V, Booser D et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:1800–1808.
: Soule SE, Miller KD, Porcu P et al. Combined anti-microtubule therapy: a phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer. Ann Oncol 2002; 13:1612–1615
: Seidman AD, Hudis CA, Albanel J et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998; 16:3353–3361.
: Wist EA, Sommer HH, Ostenstad B et al. Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer. Acta Oncol 2004;43:11–14.
: Lombardi D, Crivellari D, Scuderi C et al. Long-term, weekly one-hour infusion of paclitaxel in patients with metastatic breast cancer: a phase II monoinstitutional study. Tumori 2004; 90:285–288.
: Akerley W, Sikov WM, Cummings F et al. Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report. Semin Oncol 1997;24(suppl 17): S17-87–S17-90.
: Perez EA, Vogel CL, Irwin DH et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001; 19:4216–4223.
: ten Tije AJ, Smorenburg CH, Seynaeve C et al. Weekly paclitaxel as firstline chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial. Eur J Cancer 2004; 40:352–357.
: Sikov WM, Akerley W, Kahanic S et al. Multicenter, 3-arm randomized study of high-dose weekly paclitaxel (HDWP) versus standard-dose weekly paclitaxel (SWDP) for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2002; 21:34a.
: Alexandru Eniu,ª Frances M. Palmieri,b Edith A. Perezb. Weekly Administration of Docetaxel and Paclitaxel in Metastatic or Advanced Breast Cancer. The Oncologist 2005; 10:665–685.
:. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997; 57:229-233.
: Hennequin C, Giocanti N, Favaudon V. S-phase specificity ofcell killing by docetaxel (Taxotere) in synchronised HeLacells. Br J Cancer 1995; 71:1194-1198.
: Hennequin C, Giocanti N, Favaudon V. S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells. Br J Cancer 1995; 71:1194-1198.
: CancerEst, APHP Tenon, Medical Oncology, Paris, France.Preclinical Pharmacology of the Taxanes: Implications of the Differences the Oncologist 2004;9(suppl 2):3-8
: Burstein HJ, Manola J, Younger J et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000; 18:1212-1219.
: Riou JF,Petitgenet O,Comneau C et al.Cellular uptake and efflux of docetaxel (Taxotere®) and paclitaxel (Taxol®) in P388 cell line. Proc Am Assoc Cancer Res 1994; 35:385.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).